Vanda Pharmaceuticals Inc. (VNDA) Insider Mihael Hristos Polymeropoulos Sells 191,760 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider Mihael Hristos Polymeropoulos sold 191,760 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares in the company, valued at approximately $15,787,274.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded down $0.05 during midday trading on Friday, hitting $15.55. 385,500 shares of the company’s stock were exchanged, compared to its average volume of 550,667. Vanda Pharmaceuticals Inc. has a fifty-two week low of $11.90 and a fifty-two week high of $18.99. The company has a market capitalization of $700.87, a P/E ratio of -50.16 and a beta of 1.29.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The business had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same quarter last year, the firm earned ($0.01) earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.44 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc increased its stake in shares of Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares in the last quarter. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Vanda Pharmaceuticals during the third quarter valued at approximately $277,000. Voya Investment Management LLC increased its stake in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its stake in shares of Vanda Pharmaceuticals by 46.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 6,487 shares in the last quarter. 88.43% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. Oppenheimer set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Piper Jaffray Companies increased their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, September 14th. Finally, ValuEngine downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $21.50.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://transcriptdaily.com/2018/01/05/vanda-pharmaceuticals-inc-vnda-insider-mihael-hristos-polymeropoulos-sells-191760-shares-of-stock.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply